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www.sciencemag.org/content/350/6262/823/suppl/DC1 Materials and Methods Table S1 Figs. S1 to S13 Captions for Movies S1 to S12 References (31-38) Movies S1 to S12 The nucleotide-binding oligomerization domain-like receptor (Nlrp) 6 maintains gut microbiota homeostasis and regulates antibacterial immunity. We now report a role for Nlrp6 in the control of enteric virus infection. Nlrp6 −/− and control mice systemically challenged with encephalomyocarditis virus had similar mortality; however, the gastrointestinal tract of Nlrp6 −/− mice exhibited increased viral loads. Nlrp6 −/− mice orally infected with encephalomyocarditis virus had increased mortality and viremia compared with controls. Similar results were observed with murine norovirus 1. Nlrp6 bound viral RNA via the RNA helicase Dhx15 and interacted with mitochondrial antiviral signaling protein to induce type I/III interferons (IFNs) and IFN-stimulated genes (ISGs). These data demonstrate that Nlrp6 functions with Dhx15 as a viral RNA sensor to induce ISGs, and this effect is especially important in the intestinal tract.
N ucleotide oligomerization domain (NOD)-like receptors (NLRs) play a central role in the immune response to diverse microorganisms and react to environmental insults and cellular danger signals (1, 2) . Some NLRs contribute to antiviral immunity. NOD2 recognizes single-stranded RNA (ssRNA) viruses to induce type I interferons (IFNs) via mitochondrial antiviral-signaling protein (MAVS) (3), and the NLRP3 inflammasome is crucial for the control of diverse viral infections in vivo (4-7). Several NLRs, on the other hand, dampen antiviral immune responses. NLRX1 and NLRC5 negatively regulate type I IFNs and nuclear factor kB (NF-kB) signaling via distinct molecular mechanisms (8) (9) (10) (11) (12) ; NLRC3 attenuates Toll-like receptor signaling and the stimulator of interferon genes (STING)-mediated anti-DNA virus immune signaling (13, 14) . A role for Nlrp6 in the regulation of antibacterial immune responses has recently been documented (15) (16) (17) (18) ; however, whether Nlrp6 regulates viral infection has not yet been elucidated.
Nlrp6 exhibits a tissue-and cell-type-specific pattern of expression, with the highest level in intestinal epithelial cells (IECs) (15) (figs. S1 and S2).
We therefore determined whether Nlrp6 plays a prominent role in inhibiting enteric virus infection at the intestinal interface. We used a (+) ssRNA virus, encephalomyocarditis virus (EMCV), which is transmitted via the fecal-oral route in nature. We infected both wild-type (WT) and Nlrp6 −/− mice with EMCV systemically via intraperitoneal injection and noted that the survival curve of Nlrp6 −/− mice was similar to that of WT animals (Fig. 1A) . Viral dissemination was also the same in the blood, brains, and hearts of Nlrp6 −/− and WT mice. The intestinal viral burden of Nlrp6 −/− mice was, however, higher than that of WT animals (Fig. 1B) -suggesting that Nlrp6 plays an important role in limiting EMCV replication at this location. In support of this, Nlrp6 mRNA expression was much higher in the intestines than other tissues after EMCV infection (Fig.  1C) . We therefore reasoned that Nlrp6 prevents systemic infection and mortality when EMCV is delivered orally to its principal site of infectionthe intestine. Indeed, Nlrp6 −/− mice were more susceptible to oral infection with EMCV than WT animals ( Fig. 1D and Fig. 3E ).
Alterations in microbiota and inflammasome activation are two potential processes that may influence the ability of Nlrp6 −/− mice to control intestinal EMCV infection. The intestinal microbial ecology of Nlrp6 −/− mice is different from that of WT mice (15) , which could affect antiviral immunity. We therefore cohoused mice for 4 weeks before EMCV infection, which we previously showed was sufficient to equilibrate the microbiota between WT and Nlrp6 −/− mice. WT and Nlrp6 −/− mice had similar levels of TM7 and Prevotellacae bacteria (15) after cohousing ( fig. S3A ), indicating stabilization of the microbiota. Nlrp6 −/− mice, however, died of EMCV infection more rapidly than WT and cohoused WT animals (Fig. 1D) , and viremia was~10-fold higher in Nlrp6 −/− than WT animals (Fig. 1E) . When inoculated systemically via intraperitoneal injection, EMCV loads in the intestines of cohoused Nlrp6 −/− mice were also more than 10-fold higher than those of cohoused WT animals (Fig. 1F) S3B ). These data demonstrate that the increased viral susceptibility of Nlrp6 −/− mice is not a result of altered intestinal microbial ecology. To extend our finding further, we examined another enteric virus, murine norovirus 1 (MNV-1), a (+) ssRNA virus. MNV-1 was rapidly cleared by the innate immune system in WT mice (19) but persisted much longer in Nlrp6 −/− mice ( fig. S3 , C to E). Nlrp6 initiates inflammasome signaling via caspase-1. We therefore determined whether Nlrp6 requires caspase-1 to control EMCV at the intestinal epithelia. In agreement with a previous report (20) , following EMCV challenge, the survival of Casp1
−/− and WT mice was similar (Fig. 1D) . These data suggest that intestinal Nlrp6 controls EMCV infection by an alternative mechanism.
To understand how Nlrp6 contributes to antiviral innate immune responses, we used an Nlrp6 antibody to immunoprecipitate Nlrp6 binding partners from mouse primary IECs and a FLAGNlrp6 overexpression system in human embryonic kidney 293 T (HEK293T) cells. We identified DEAH (Asp-Glu-Ala-His) box helicase 15 (Dhx15) by mass spectrometry ( fig. S4 ) and confirmed it using a specific antibody to Dhx15 ( Fig. 2A and fig.  S5A ). Glutathione S-transferase-Dhx15 expressed in Escherichia coli pulled down FLAG-Nlrp6 expressed using a mammalian in vitro translation system ( fig. S5B ), suggesting a direct interaction. Nlrp6 is composed of three functional domains: an N-terminal pyrin domain (PYD), a NACHT domain, and a C-terminal leucine-rich repeat domain (LRR). Each individual domain failed to bind Dhx15 when compared with full-length Nlrp6 ( fig. S5C) . A fragment encompassing the NATCH and NACHT-associated domain (NAD) interacted with Dhx15 (Fig. 2B ). NLRP3, a close relative of Nlrp6, did not interact with Dhx15, demonstrating specificity ( fig. S5C ).
Dhx15 is a putative pre-mRNA-splicing factor and adenosine triphosphate (ATP)-dependent RNA helicase that modulates antiviral immune responses via MAVS, an adaptor protein for retinoic acid inducible gene 1 (RIG-I)-like receptors (RLRs) (21, 22) . We reasoned that the Nlrp6-Dhx15 complex might use MAVS to trigger type I IFN responses. Indeed, FLAG-Nlrp6 bound endogenous MAVS, as did Nlrp3 ( (23)) and RIG-I (24-27) (Fig.  2C ). The negative controls FLAG-NLRC5 (11) or Nlrp10 did not coprecipitate with MAVS ( fig. S5D ), confirming the specificity of the Nlrp6-MAVS interaction. Because Dhx15 is a putative RNA helicase and viral RNA sensor (22), we then determined whether Nlrp6-Dhx15 forms a viral RNAsensing complex. Both Nlrp6 and Dhx15 showed high affinity for viral RNA (Fig. 2D and fig. S6A ). The Nlrp6 NACHT domain was sufficient for RNA binding but weaker than full-length Nlrp6 (fig. S6B). To exclude nonspecific binding due to overexpression, we examined endogenous Nlrp6 binding to viral RNA in WT and FLAG-Nlrp6 knock-in mice ( fig. S2 ). Both Nlrp6 and FLAG-Nlrp6 was coimmunoprecipitated with EMCV RNA from infected IECs (Fig. 2E and fig. S6C ). Because the RNA binding capacity of Dhx15 was much greater than that of Nlrp6, we reasoned that Nlrp6-RNA binding was dependent on Dhx15. Indeed, the amount of Nlrp6-bound viral RNA was reduced significantly in Dhx15 small interfering RNA (siRNA)-treated cells (Fig. 2F) . In contrast, Dhx15-RNA binding was not altered in Nlrp6 −/− cells ( fig.  S6D ). Like Dhx15 (22) , Nlrp6 bound only RNA but not DNA viruses ( fig. S6E ). To assess the nature of viral RNA bound by Nlrp6, we tested several synthetic RNA analogs. Nlrp6 preferably bound the long double-stranded RNA (dsRNA) analog polyinosinic-polycytidylic acid (polyIC) (Fig. 2G ). To provide in vivo evidence for a functional interaction between MAVS, Dhx15, and Nlrp6, we examined MAVS-Dhx15 interactions in WT and Nlrp6
IECs. Consistent with a previous report (22) , MAVS binding to Dhx15 was enhanced by EMCV infection in WT IECs, but the interaction was weaker in Nlrp6 −/− (Fig. 2H) . were also much more susceptible to EMCV administered orally when compared with WT mice (Fig. 2I ). These data suggest that the Dhx15-Nlrp6-MAVS axis plays an important role in restricting EMCV infection of the intestine.
To validate a role for Nlrp6 in Dhx15-Mavsmediated antiviral immunity, we examined the expression of type I/III IFN-induced genes (ISGs). The mRNA and protein expression of a number of ISGs was reduced in Nlrp6 −/− IECs compared with WT ( fig. S7A and Fig. 3, A and B) . Although both types I and III IFNs can elicit antiviral responses, type III IFNs are particularly critical for controlling viral infection in IECs (28) (29) (30) . IFN-l (also known as IL-28a) protein and mRNA, and Ifnb mRNA, were reduced in Nlrp6 -/-intestines after EMCV infection ( fig. S7B ). ISG mRNA amounts were, however, similar in other WT and Nlrp6 −/− tissues ( fig. S8 ).
To (Fig. 3, C and  D, and fig. S10, A and B) . We also observed a decrease in polyIC-induced Ifnb1 expression in Nlrp6 −/− compared with Nlrp6 -/+ MEFs ( fig. S10C ). In agreement with the results from Nlrp6 −/− cells, overexpression of Nlrp6 enhanced Ifnb1 and Il6 expression modestly ( fig. S11 ). All these data demonstrate a pivotal role for Nlrp6 in inducing type I/III IFNs and ISGs. Type III IFNs are particularly critical for control of viral infection of IECs (28) (29) (30) . Indeed, exogenous IFN-l fully protected WT and Nlrp6 −/− mice against lethal EMCV infection and reduced viremia significantly (Fig. 3E) . We next determined whether the antiviral function of Nlrp6 is specific for RNA viruses. Neither herpes simplex virus-1 (HSV-1) titers nor Ifnb1 expression in Nlrp6 −/− was different from those in Nlrp6
-/+ cells ( fig. S12A ). IFN-a, polydAT, or lipopolysaccharide-induced ISGs or cytokine expression in Nlrp6 −/− was also similar to that in Nlrp6 -/+ MEFs ( fig. S12 , B to D). As viral infections and the ligands that can induce robust type I IFN expression also upregulated Nlrp6 expression (Fig. 3C and figs . S10C, S12C, and S13), we reasoned that Nlrp6 per se might be an ISG. Indeed, induction of Nlrp6 mRNA expression by EMCV or polyIC treatment was almost abolished in Irf3/7 −/− or Ifnar1 −/− MEFs. Consistent with this, recombinant IFN-a, but not tumor necrosis factor-a (TNF-a) was able to induce Nlrp6 expression vigorously, suggesting that interferon regulatory factor (IRF)/ IFN signaling, but not NF-kB signaling controls Nlrp6 expression (Fig. 4 and fig. S14A ). Nlrp6 mRNA expression was also induced by recombinant IFN-l2 ( fig. S14B) . These results indicate that Nlrp6 expression is regulated by type I/III IFNs via IRF3/7.
The above-mentioned data demonstrate that Dhx15-Nlrp6 senses long dsRNA in the cytoplasm (Fig. 2G) , a well-established feature for MDA5. We then determined whether Nlrp6-mediated signaling is also dependent on MDA5. siRNA knockdown of Nlrp6 reduced Ifnb1 and Isg15 mRNA expression after polyIC stimulation in . S15D ). We next examined the relative antiviral role for MDA5 in the intestine in comparison with Nlrp6. The viral loads in both Nrp6 −/− and Mda5 −/− IECs were similar but were much higher than those in WT mice ( fig. S15E ). These results, in conjunction with the Nlrp6, Dhx15, and MDA5 expression data ( fig. S1 ), suggest that Dhx15-Nlrp6 constitutes the first line of anti-EMCV defense in the intestinal epithelia, whereas MDA5 is dominant in myeloid cells.
Our results demonstrate that Nlrp6 controls enteric virus infection in the intestine by interacting with an RNA sensor, Dhx15, to trigger MAVSdependent antiviral responses. This inflammasomeindependent response provides a mechanism for Nlrp6 to elicit pleotropic effects in the host and demonstrates its importance against diverse classes of microbes. 
*
In healthy individuals, the intestinal microbiota cannot access the liver, spleen, or other peripheral tissues. Some pathogenic bacteria can reach these sites, however, and can induce a systemic immune response. How such compartmentalization is achieved is unknown. We identify a gut-vascular barrier (GVB) in mice and humans that controls the translocation of antigens into the bloodstream and prohibits entry of the microbiota. Salmonella typhimurium can penetrate the GVB in a manner dependent on its pathogenicity island (Spi) 2-encoded type III secretion system and on decreased b-catenin-dependent signaling in gut endothelial cells. The GVB is modified in celiac disease patients with elevated serum transaminases, which indicates that GVB dismantling may be responsible for liver damage in these patients. Understanding the GVB may provide new insights into the regulation of the gut-liver axis.
U pon ingestion, food antigens can access the lymphatics to reach the mesenteric lymph nodes (MLNs) (1) and the blood stream (portal vein) to reach the liver (2). In contrast, the microbiota cannot access the liver (3) and can reach the spleen only when the MLNs are excised (4) . This suggests that the microbiota are actively excluded from the bloodstream and that the MLNs provide a firewall for the systemic dissemination of the microbiota from the lymphatics (5). What determines antigen access to the bloodstream is unknown.
We hypothesized the existence of a gutvascular barrier (GVB) that might control the type of antigens that are translocated across blood endothelial cells (ECs) to reach the portal vein. To evaluate the presence of such a barrier, we injected mice intravenously with fluorescein isothiocyanate (FITC)-dextran of different molecular sizes and analyzed leakage of the dye into the intestine. We observed that there is an endothelial barrier that discriminates between differently sized particles of the same nature. FITC-dextran of 4 kD freely diffused through the ECs, whereas FITC-dextran of 70 kD could not ( Fig. 1A; fig. S1 , A and B; and movies S1 and S2). However, after oral infection with Salmonella enterica serovar Typhimurium, which disseminates systemically in mice (6), 70 kD dextran was readily released from the bloodstream (Fig. 1A,  fig. S1 , and movies S3 and S4). This was not due to increased blood flow during infection, as 1-mm microspheres were retained within the vessels even after Salmonella infection ( fig. S1 , C and D, and movies S5 and S6). These results suggest the existence of a GVB that prevents the translocation of molecules of around 70 kD and that can be disrupted by Salmonella.
Endothelial barriers are characterized by the presence of elaborate junctional complexes that include tight junction (TJ) and adherens junction (AJ), which strictly control paracellular trafficking of solutes and fluids (7, 8) . Other cell types, such as pericytes or fibroblasts, can be found associated with the microvasculature and are involved in the maintenance of the vascular barrier, where they form a vascular unit (9) . To study GVB characteristics, we analyzed the composition of TJ and AJ in gut ECs. We found that enteric ECs have TJ formed by occludin, zonula occludens-1 ZO-1, cingulin, and junctional adhesion molecule-A JAM-A (Fig. 1B and fig. S2 ) and AJ formed by vascular endothelial cadherin (VE-cadherin) and b-catenin (Fig. 1C and fig. S3 ). Claudin-5 was expressed primarily in lymphatic endothelial TJ ( fig. S4 ). Claudin-12 was associated with other cell types in the lamina propria ( fig. S2 ), which probably reflects a function in ion transport rather than in sealing (10) . Finally, we found that gut ECs were surrounded by enteric glial cells expressing the intermediate filament glial fibrillary acidic protein (GFAP) and by pericytes expressing desmin (Fig.  1D and fig. S5 ). Thus, gut ECs are organized in a gut-vascular unit and express TJ and AJ proteins.
We then analyzed the expression of plasmalemma vesicle-associated protein-1 (PV1) (11), a marker of EC permeability (12, 13) . We found that gut blood ECs in the lamina propria (but not in the submucosa) did not express PV1 (Fig. 2A) . We then hypothesized that PV1 expression could be modulated upon Salmonella challenge, which would reflect the increased vessel permeability. We observed a peak of PV1 up-regulation on blood but not lymphatic vessels in the jejunum and ileum 6 hours after Salmonella infection (Fig. 2,  A and B ). This correlated with Salmonella dissemination to the liver and spleen (Fig. 2C) and
